

Dr. David Samadi explains FDA's approval of new COVID-19 antigen test with rapid results

New Antigen test for Covid 19 could be a game changer.So far majority of tests have focused on our immunity and antibody tests. First test focus on virus itself

NEW YORK, NY, UNITED STATES, May 11, 2020 /EINPresswire.com/ -- <u>Dr.</u> David Samadi explains FDA's approval of new COVID-19 antigen test with rapid results

New rapid coronavirus test may be pivotal in opening up the economy

The Food and Drug Administration took a step in the right direction helping speed up nationwide testing by granting emergency-use authorization for antigen tests for detecting the

COVID-19 virus. Developed by Quidel Corporation of San Diego, this test is able to provide an automated result within 15 minutes.

Covid-19


"This is good news on the forefront of helping reopen the economy to get American citizens back

minutes if you have it or not."



Dr. David Samadi is optimistic about some new Antigen testing for Covid 19. This can detect the presence of the virus in our body before even knowing that we have built any immunity."

Optimistic Antigen tests for Covid 19 coming to the market



Typically, the test used to diagnose COVID-19 is a polymerise chain reaction (PCR) test. A PCR test, done with a swab of a person's nose or throat, looks for genetic information that is detectable when a person is actively infected by finding viral RNA present in the body before antibodies have formed. PCR tests are quite accurate but have a downfall of being labor intensive taking longer to

analyze results.

This new test from Quidel Corp. is an antigen test using nasal swabs which looks for protein molecules on the surface of the virus. Results are much quicker but there are some issues with accuracy. Patients testing positive are usually correct but there is a rate of false negatives of up to 15%. If that happens, the FDA recommends anyone with a negative result from an antigen test should be confirmed with a PCR test.

"This new antigen test is named Sofia 2 SARS Antigen FIA," explained <u>Dr. Samadi</u>. "Right now, the goal is to ramp up manufacturing of the test by producing 1 million each week ready for use at doctor's office, urgent-care centers or even retail clinics. It's cheaper to produce than PCR tests

and has a potential of testing millions of Americans each day. This means testing can be brought to a more optimal level to better assess the safety of allowing the public to return to work, school, religious services and other activities of everyday life. People are ready to return to normal life and this new test can help speed that up." Dr. David Samadi is the Director of Men's Health and Urologic Oncology at St. Francis Hospital in Long Island. He's a renowned and highly successful board certified Urologic Oncologist Expert and Robotic Surgeon in New York City, regarded as one of the leading prostate surgeons in the U.S., with a vast expertise in prostate cancer treatment and Robotic-Assisted Laparoscopic Prostatectomy. Visit Dr. Samadi's websites at robotic oncology and prostate cancer 911.

Dr. David Samadi, M.D. roboticoncology +1 212-365-5000 email us here Visit us on social media: Facebook Twitter LinkedIn



Dr. David Samadi world renowned robotic surgeon



Dr. David Samadi Robotic Prostate Expert is expanding his Manhattan Practice Now to Long Island with Two Locations.

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.